Eli Lilly CEO tells CNBC one-third of new GLP-1 pill patients are taking Foundayo, as drugmaker ramps up production

Eli Lilly is trying to catch up in the GLP-1 pill market to Novo, which got a head start in the space. In an exclusive interview, he said the company's share of the oral market is growing week over week.

Source: CNBC

Indexed: Mon, 21 Sep 2026 23:50:33 UTC

Read original source →

Not a government entity. Not a broker or agent. Public information index only. Verify independently.